Biomea Fusion (BMEA) Osake Kurssi

Biomea Fusion, Inc. is a hematological oncology biopharmaceuticals company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers and metabolic disorders. The company is headquartered in Redwood City, California and currently employs 103 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The firm has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical covalent programs for the treatment of select cancers.